Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Go back to Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 15.18 -0.01 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.19 | 52 Week High | $19.40 | |||
| Open | $14.73 | 52 Week Low | $12.50 | |||
| Day High | $15.23 | P/E | N/A | |||
| Day Low | $14.52 | EPS | $0.00 | |||
| Volume | 115,865 | |||||
